Emeriti Pharma Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Out of Business

Emeriti Pharma General Information

Description

Developer of skin disease treatment therapies intended to treat rosacea and psoriasis with medical advancement. The company's cream contains active drug substances that offer treatment for any inflammatory skin disease, especially rosacea, and also research on idiopathic pulmonary fibrosis, enabling patients to get advanced medicinal products for faster recovery.

Contact Information

Website
emeritipharma.se
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • AZ Bioventure Hub
  • C/o AstraZeneca
  • 431 83 Molndal
  • Sweden
+46 070-695
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • AZ Bioventure Hub
  • C/o AstraZeneca
  • 431 83 Molndal
  • Sweden
+46 070-695

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Emeriti Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Out of Business Completed Out of Business
3. Early Stage VC 20-Dec-2016 Completed Clinical Trials - General
2. Early Stage VC 10-Nov-2015 $238K $238K Completed Clinical Trials - General
1. Accelerator/Incubator Completed Startup
To view Emeriti Pharma’s complete valuation and funding history, request access »

Emeriti Pharma Patents

  • 16

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

Emeriti Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201820529-D0 Compounds and combinations for the treatment of rosacea Inactive 17-Dec-2018
GB-201721278-D0 Compunds and combinations for the treatment of rosacea Inactive 19-Dec-2017
AU-2015363700-A1 3-(piperidin-4-yl)-isoxazol-3(2h)-ones for treatment of dermatologic disorders Inactive 19-Dec-2014
CA-2967268-A1 3-(piperidin-4-yl)-isoxazol-3(2h)-ones for treatment of dermatologic disorders Inactive 19-Dec-2014
EP-3233189-A1 3-(piperidin-4-yl)-isoxazol-3(2h)-ones for treatment of dermatologic disorders Inactive 19-Dec-2014 A61K31/454
To view Emeriti Pharma’s complete patent history, request access »

Emeriti Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Emeriti Pharma FAQs

  • When was Emeriti Pharma founded?

    Emeriti Pharma was founded in 2015.

  • Where is Emeriti Pharma headquartered?

    Emeriti Pharma is headquartered in Molndal, Sweden.

  • What is the size of Emeriti Pharma?

    Emeriti Pharma has 4 total employees.

  • What industry is Emeriti Pharma in?

    Emeriti Pharma’s primary industry is Drug Discovery.

  • Is Emeriti Pharma a private or public company?

    Emeriti Pharma is a Private company.

  • What is Emeriti Pharma’s current revenue?

    The current revenue for Emeriti Pharma is .

  • How much funding has Emeriti Pharma raised over time?

    Emeriti Pharma has raised $562K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process